Day One Biopharmaceuticals Inc.
DAWN | NASDAQ
$21.53
$0 (0.00%)
Apr 24, 2026, 9:30 AM ET · Market open
Company Profile
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Key Executives
| Name | Position |
|---|---|
| Jeremy Bender | Chief Executive Officer, President & Director |
| Jaa Roberson | Chief People Officer |
| John Stubenrauch | Chief Technology Officer |
| Adam Dubow | General Counsel, Chief Compliance Officer & Secretary |
| Charles N. York | COO & CFO |
| Davy Chiodin | Chief Development Officer |
| Elly Barry | Chief Medical Officer |
| Heather Adkins Huet | Chief Scientific Officer |
| Joey Perrone | Senior Vice President of Finance & Investor Relations |
| Lauren Merendino | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 26, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Mar 26, 2026 | SC TO-T/A | [Amend] Filing |
| Mar 26, 2026 | SC 14D9 | Filing |
| Mar 26, 2026 | SC TO-T | Filing |
| Mar 23, 2026 | SC TO-C | Filing |
| Mar 19, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Mar 09, 2026 | 8-K/A | [Amend] Current Report |
| Mar 09, 2026 | SC TO-C | Filing |
| Mar 06, 2026 | SC TO-C | Filing |
| Mar 06, 2026 | SC14D9C | Filing |
Day One Biopharmaceuticals Inc.
| Country | United States |
| IPO Date | May 26, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 181 |
| CEO | Jeremy Bender |
Contact Details
395 Oyster Point Boulevard Brisbane,
California 94080 United States
Stock Details
| Ticker Symbol | DAWN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001845337 |
| CUSIP Number | 23954D109 |
| ISIN Number | US23954D1090 |
| SIC Code | 2834 |
Recent News
- 5 months ago / prnewswire.comServier completes the acquisition of Day One Biopharmaceuticals
- 6 months ago / businesswire.comDay One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN
- 7 months ago / prnewswire.comAre DAWN and TALK Obtaining Fair Deals for their Shareholders?
- 7 months ago / zacks.comDAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier
- 7 months ago / fool.comStock Market Today, March 6: Energy Stocks Rise as Oil Closes Over $90 on Middle East Tensions
- 7 months ago / newsfilecorp.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Day One Biopharmaceuticals, Inc. (DAWN)
- 7 months ago / prnewswire.comShareholder Alert: The Ademi Firm investigates whether Day One Biopharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders
- 7 months ago / prnewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN)
- 7 months ago / businesswire.comDAWN Stock Alert: Halper Sadeh LLC is Investigating Whether Day One Biopharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
- 7 months ago / benzinga.comDay One Shares Surge After $2.5B Servier Deal
Add to Watchlist
Select watchlists to add or remove DAWN